title: [Generalized cutaneous candidiasis in newborn at term].
abstract: BACKGROUND
  Cutaneous candidiasis is a disease that affects children as well as adults. The presentation may be localized or systemic, and with multiple etiological agents. The most prevalent infecting species in children differs from that of the adult.
  
  
  OBJECTIVE
  A case is presented where a congenital cutaneous candidiasis was transmitted to the child during birth.
  
  
  METHODS
  A full term newborn was exposed to a subclinical vaginal candidiasis infection, and 24 hr after birth, developed congenital cutaneous candidiasis. The etiological agent was Candida albicans, and was associated with sepsis and respiratory distress. Blood cultures, cutaneous biopsy of vesicular lesions, blood tests and lumbar puncture were performed.
  
  
  RESULTS
  Biochemistry and blood count showed a CRP of 5.7 mg/dl, leukocytosis with left shift and mild anemia. After 24 hr, the blood analyses showed an increase in a CRP (7.8 mg/dl) and increased progressively for three days; consequently, a lumbar puncture was performed. Blood culture was positive for Staphylococcus aureus. Cutaneous biopsy confirmed the cutaneous candidiasis.
  
  
  CONCLUSIONS
  The early diagnosis is essential to prevent complications derived by the Candida albicans in newborns.
authors.affiliation: Hospital Universitario San Cecilio, Granada, España.
authors.forename: Husein Husein
authors.initials: HH
authors.lastname: El Ahmed
authors.forename: Guillermo Arturo
authors.initials: GA
authors.lastname: Cañadas-De la Fuente
authors.forename: Rafael
authors.initials: R
authors.lastname: Fernández-Castillo
authors.forename: Emilio
authors.initials: E
authors.lastname: González-Jiménez
authors.forename: Jesús
authors.initials: J
authors.lastname: Cantero-Hinojosa
authors.forename: Marita
authors.initials: M
authors.lastname: Lardón-Fernández
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D001639:Bicarbonates / Q000008:administration & dosage / Q000627:therapeutic use; D002179:Candidiasis, Cutaneous / Q000150:complications / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000635:transmission; D002181:Candidiasis, Vulvovaginal / Q000635:transmission; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000382:microbiology; D002710:Chlorhexidine / Q000627:therapeutic use; D060085:Coinfection; D042241:Early Diagnosis; D004643:Emollients / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D008825:Miconazole / Q000008:administration & dosage / Q000627:therapeutic use; D011196:Potassium Permanganate / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012120:Respiration Disorders / Q000209:etiology; D018805:Sepsis / Q000209:etiology; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000302:isolation & purification; D007507:Therapeutic Irrigation
chemical_list: D000890:Anti-Infective Agents; D001639:Bicarbonates; D004643:Emollients; D011196:Potassium Permanganate; D008825:Miconazole; D002439:Cefotaxime; D002710:Chlorhexidine